InflaRx N.V..
IFRX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
InflaRx N.V. is a biopharmaceutical company dedicated to discovering and developing novel therapeutics for the treatment of life-threatening inflammatory diseases. The company focuses on the clinical development of its proprietary anti-C5a antibody, vilobelimab (IFX-1), which targets the complement ...Show More
Better Health for All
0
No evidence available to assess InflaRx N.V. on Better Health for All.
Fair Money & Economic Opportunity
0
InflaRx N.V. (IFRX.US) is described as a biopharmaceutical company. The ethical value 'Fair Money & Economic Opportunity' assesses companies involved in lending, insuring, moving, or storing money. The provided articles do not contain any information about InflaRx N.V. engaging in financial services, offering consumer credit products, or implementing financial inclusion initiatives.
1
Therefore, no specific data points relevant to any of the KPIs for this value could be extracted from the evidence, leading to the omission of all KPIs.
Fair Pay & Worker Respect
40
The company's CEO to median employee pay ratio was 9.5 in 2024.
1
This ratio has been consistently low, with 10.1 in 2023, 9.9 in 2022, 9.2 in 2021, and 9.8 in 2020.
2
Fair Trade & Ethical Sourcing
0
No quantitative data or specific facts directly relevant to Fair Trade & Ethical Sourcing metrics, such as fair trade certifications, audit frequencies, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend, were found in the provided articles.
1
The available documents focus on financial performance, corporate governance, clinical trials, and securities offerings, without addressing these specific supply chain practices.
2
Honest & Fair Business
0
No evidence available to assess InflaRx N.V. on Honest & Fair Business.
Kind to Animals
-60
The company explicitly uses animal testing as part of its drug development process, including preclinical studies, long-term toxicological studies in several animal species for INF904, and acute inflammatory animal models across various species.
1
Animal models of sepsis are also used to test anti-C5a treatment.
2
There is no explicit animal testing policy stated in the provided documents, nor any mention of transparent reduction targets or alternative testing methods.
3
The company's ESG risk profile confirms 'Yes' for animal testing.
4
The volume of animals used is not specified, but the routine and varied use of animal models indicates a significant volume without transparent reduction goals.
5
No War, No Weapons
0
No evidence available to assess InflaRx N.V. on No War, No Weapons.
Planet-Friendly Business
0
No specific, quantifiable data points were found in the provided articles for any of the environmental KPIs.
1
The articles explicitly state a lack of data on environmental, social, and governance (ESG) metrics, sustainability metrics, specific environmental impact assessments, and detailed supply chain transparency.
2
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding InflaRx N.V.'s performance or policies related to 'Respect for Cultures & Communities'. The articles primarily contain financial information, employee biographies, and details about a product commitment program, none of which address community engagement, cultural preservation, local employment, or grievance mechanisms for community concerns.
Safe & Smart Tech
0
The company's privacy policy outlines standard user rights under GDPR, including the right to access, rectify, erase, restrict processing, object to processing, and data portability, indicating industry-standard user data control.
1
For data minimization, the policy states that data is collected for specific purposes and retained for defined periods, such as application documents for up to 6 months after rejection and contact form data for up to 6 months, aligning with standard practices.
2
The company also states compliance with Dutch and EU regulations, including the Dutch Corporate Governance Code (DCGC), and HIPAA and GDPR requirements for clinical trials, which represents basic compliance with applicable regulations.
3
Zero Waste & Sustainable Products
0
No evidence was found in the provided articles regarding InflaRx N.V.'s performance on any of the 'Zero Waste & Sustainable Products' KPIs. The articles either focused on general industry news, marketing services, domain purchasing, or were inaccessible due to throttling.
1